Archive - The PopVax Chronicles

Potent, broadly-protective flu vaccines to protect against potential pandemic influenza viruses such as H5N1

PopVax’s influenza vaccine designs elicit as much as 250x greater antibody titer against seasonal strains than existing approved flu vaccines, as well…

Jan 3 •

December 2024

PopVax updates – NIH NIAID will conduct the Phase I trial for our COVID-19 vaccine + Gates Foundation funding for our thermostable mRNA…

We have some exciting news to share:

Dec 22, 2024 •

August 2023

The unlikely, inevitable founding of PopVax, Part I: Three meetings and six million funerals

Broadly-protective mRNA vaccines to save millions of lives

Aug 20, 2023 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts